Michael B. Hoffman - 17 Nov 2023 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)

Role
Director, 10%+ Owner
Signature
/s/ Maria Maccecchini Attorney-in-Fact
Issuer symbol
ANVS
Transactions as of
17 Nov 2023
Net transactions value
$0
Form type
4
Filing time
03 Jul 2024, 17:16:18 UTC
Previous filing
11 Apr 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANVS Stock Option (right to buy) Award $0 +29,600 $0.000000 29,600 17 Nov 2023 Common Stock 29,600 $6.07 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
F2 The stock option shall vest immediately upon grant date.